• Find people
• Intranet

Urological Cancer Joaquim Bellmunt

The Urological Cancer Research Group (GRECU) is a multidisciplinary team focused on clinical and translational research in urological cancer, primarily centered on bladder and prostate cancer.

GRECU has gathered some of the best translational researchers in their respective fields. The multidisciplinary nature of our team allows us to tackle translational projects, addressing both clinical, molecular and technical aspects with the maximum rigor and scientific quality.

Our group is at the global forefront in the molecular characterization of bladder and prostate cancer, exploring the relationship with treatment response, prognosis and overall survival.

In addition, we are actively involved in the development and validation of predictive biomarkers and novel therapeutic strategies, often in collaboration with leading national and international institutions. Through participation in multicenter clinical trials and cutting-edge research initiatives, GRECU aims to contribute directly to improving patient care and advancing precision oncology in the genitourinary field.

The members of GRECU have collectively authored hundred of high impact scientific publications, demonstrating sustained research productivity across various disciplines. These works garnered thousands of citations, reflecting the relevance, visibility, and impact of their contributions within the scientific community. Together, our studies reflect significant advancements in molecular characterization and the development of new therapies for both bladder and prostate cancer, opening up new possibilities for more personalized and effective treatments.

Research lines

• In bladder cancer, team members conduct key research highlighting the importance of biomarkers and immunotherapy strategies to improve prognosis and treatment response. Our research also contribute to important clinical trials that demonstrate benefit in patients who had failed chemotherapy.
• In prostate cancer, we focus on the analysis of genomic and transcriptomic alterations and their association with adverse clinical features. Immunohistochemical biomarkers are also the focus of our research, seeking significant correlations with prostate cancer prognosis to improve patient clinical management.

Leadership and Funding

Several team members successfully lead competitive grants, reflecting the group's strong research leadership and funding capacity. These grants underscore our ongoing commitment to advancing cancer research and improving the understanding and treatment of bladder and prostate cancers through collaborative and innovative projects.

GRECU members have made substantial contributions that have directly influenced clinical practice and healthcare decision-making, both at the European and international levels. Their work plays a key role in the development and review of international clinical guidelines, consensus documents, and risk stratification tools, particularly in the treatment of bladder and urothelial cancer. These contributions demonstrate the group's commitment to translational research with real-world impact, helping to define current standards of care and improve patient outcomes.

Commitment to Knowledge Transfer and Education

As part of its commitment to knowledge transfer and international collaboration, GRECU actively contribute to the organization of high-level scientific events focused on genitourinary oncology.

GRECU membres also play an active role in academic mentorship, supervising both PhD and master’s students as they develop and complete their research projects in the field of genitourinary oncology.